Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.280
-0.030 (-2.29%)
Dec 20, 2024, 4:00 PM EST - Market closed
Cardiol Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
6
Market Cap
106.17M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCRDL News
- 2 days ago - PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis - GlobeNewsWire
- 4 weeks ago - Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024 - Newsfile Corp
- 5 weeks ago - Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index - GlobeNewsWire
- 2 months ago - Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis - Newsfile Corp
- 2 months ago - Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option - Newsfile Corp
- 2 months ago - Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares - Newsfile Corp
- 2 months ago - Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares - Newsfile Corp
- 2 months ago - Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares - Newsfile Corp